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Objectives: T cells play a key role in the pathogenesis of early systemic sclerosis. This 
study assessed the safety and efficacy of abatacept in patients with diffuse cutaneous 
systemic sclerosis (dcSSc).
Methods: A 12-month, randomized, double-blind, placebo-controlled trial with 
participants randomized in a 1:1 ratio to either abatacept 125 mg subcutaneous or 
matching placebo, stratified by duration of dcSSc. Escape therapy was allowed at six 
months for worsening disease. The co-primary end points were change in modified 
Rodnan skin score (mRSS) and safety over 12 months. Treatment differences in 
longitudinal outcomes were assessed using linear mixed models, with outcomes 
censored after initiation of escape therapy. Baseline skin tissue was classified into 
intrinsic gene expression subsets.
Results: Among 88 participants, the adjusted mean change in mRSS at 12 months was 
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treatment difference of -1.75 units (p=0.28). Two secondary outcome measures (HAQ-
DI and a composite measure) were clinically and statistically significant favoring 
abatacept. A larger proportion of placebo subjects required escape therapy relative to 
abatacept (36% vs. 16%). Decline in mRSS over 12 months was clinically and 
significantly higher in abatacept vs. placebo for the Inflammatory (p<0.001) and Normal-
like skin gene expression subsets (p=0.03). 35 participants in the abatacept versus 40 
in the placebo had adverse events (AEs), including two and one deaths, respectively. 
Conclusions: In this Phase 2 trial, abatacept was well tolerated, but change in mRSS 
was not statistically significant. Secondary outcome measures, including gene 
expression subsets, showed some evidence in favor of abatacept. These data should 
be confirmed in a Phase 3 trial.
Funding: This trial was funded by Bristol Myers-Squibb. The biomarker data was 
funded by NIH/NIAID (Clinical Autoimmunity Center of Excellence).
Introduction 
Systemic sclerosis (SSc, scleroderma) is an immune-mediated rheumatic disease 
characterized by fibrosis in the skin and internal organs, and by vasculopathy[1]. It has 
the highest case fatality of any rheumatic disease. One sub classification of this 
disease, diffuse cutaneous SSc (dcSSc), has a 10-year mortality rate of 50%[1]. There 
are no licensed treatments for SSc; disease management is focused on organ-specific 
complications[2].
Published evidence supports the concept that T cells play a key role in the 
pathogenesis of dcSSc, including cutaneous disease and at least some of the visceral 
complications[3-5]. Skin biopsies obtained from dcSSc patients early in their disease 
demonstrate a perivascular, mononuclear cell infiltrate comprised of T cells and 
macrophages[3, 4]. The numbers of T cells have been found to correlated with the 
degree of skin thickening in the biopsy sites. T cells are the dominant population of 
lymphocytes in the skin, and are activated in SSc. The adaptive immune system gene 
expression signature is higher in the skin in early dcSSc than in established dcSSc[6]. 
Animal studies support the role of abatacept (cytotoxic T lymphocyte-associated antigen 
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attenuates skin and lung fibrosis in models of scleroderma[7, 8]. In addition, a 24-week, 
placebo-controlled pilot study (N=10) showed that the abatacept was safe [9]. When 
incorporating the molecular gene expression data in skin, 4 of 5 participants with the 
Inflammatory subset improved on abatacept[9].
Based on these observations, we conducted a Phase 2 trial to evaluate weekly 
subcutaneous (SC) abatacept vs. placebo in dcSSc. The primary objectives were to 
assess safety and efficacy on skin thickening, as assessed by mRSS, in a 12-month 
double-blind study in patients with relatively early disease (< 36 months).  We 
hypothesized baseline mRSS scores might be lower in patients with early disease 
duration (< 18 months) and higher in longer disease duration (>18 and < 36 months) 
and that the impact of abatacept might differ by duration of disease.  We stratified by 
disease duration to control for disease duration in the overall analysis, while allowing us 
to explore the ability of abatacept to prevent or reverse dcSSc progression in patients 
with early disease duration and to reverse established disease in patients with longer 
disease duration. In addition, our a priori hypothesis was that participants with 




This was a Phase 2, investigator-initiated, randomized, double-blind, placebo-
controlled trial of abatacept in patients with dcSSc (clinicaltrials.gov NCT02161406). 
dcSSc was defined as skin thickening, proximal as well as distal, to the elbows or knees 
with or without involvement of the face and neck at the time of study entry. Study 
participants were treated for 12 months on double-blind study medication, and were 
offered an additional six months of open-label SC abatacept therapy. The end-of-study 
event was a telephone call 30 days after the last dose of study drug to discuss any 
adverse events (AEs) that may have occurred. The Sponsor, Dinesh Khanna, MD, MSc, 
received an Investigational New Drug exemption from the Food and Drug 
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approved the Study Protocol (available in the Protocol Section) before the research 
commenced. The study was conducted in accordance with the Declaration of Helsinki 
and with Good Clinical Practice.  
Study Participation Criteria
Key inclusion criteria were: (1) adult participant, age 18 years and older; (2) 
diagnosis of SSc, as defined using the 2013 American College of 
Rheumatology/European Union League Against Rheumatism classification of SSc[10] 
and dcSSc, as defined by LeRoy and Medsger[11]; and (3) disease duration of ≤36 
months (defined as time from the first non−Raynaud phenomenon manifestation). For 
disease duration of ≤18 months, an mRSS ≥10 and ≤35 units was required at the 
screening visit. For disease duration of >18 to ≤36 months, an mRSS of ≥15 and ≤45 
units was required along with one of the following conditions which must have been 
observed at the screening visit, compared to the patient’s last visit in the previous one to 
six months: (1) increase of ≥3 mRSS units, (2) involvement of one new body area with 
increase of ≥2 mRSS units, (3) involvement of two new body areas with increase of ≥1 
mRSS unit, and/or (4) presence of one or more tendon friction rubs. 
Oral corticosteroids (≤10 mg/day of prednisone or equivalent) and NSAIDs were 
permitted if the patient was on a stable dose regimen for ≥2 weeks prior to and including 
the baseline visit, but no background immunomodulatory therapies were allowed. More 
details are available in the Study Protocol (available in the Protocol Section). Written 
informed consent was obtained from each participant.
Randomization and Masking
Eligible participants were randomized in a 1:1 ratio to either 125 mg SC abatacept or 
matching placebo (provided by Bristol-Myers Squibb), stratified by duration of dcSSc 
disease (<18months vs. >18 to <36 months). The first injection was given at the 
research office and the subsequent study medications were injected weekly at home. 
The Data Coordinating Center (DCC) at the University of Michigan prepared the 
randomization schedule, using computer-generated block randomization with the 
random block sizes of 2 and 4 (known only by the DCC). The study staff (including the 
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Participants were seen at regular intervals throughout the 12-month study period. 
Study assessments and their timing are summarized in the Study Protocol (see Section 
6 of the Protocol). Screening took place within 28 days before randomization. Eligible 
patients were assessed at baseline; at months 1, 3, 6, 9, and 12 in clinic; and 30 days 
after the last dose by phone (for those who did not continue into the open-label period).  
Escape therapy with immunomodulatory agents was permitted as add-on therapy to 
study medications, starting at month 6, due to worsening of the dcSSc (Protocol Page 
28). The decision to initiate escape therapy was based on investigator discretion. No 
biologic agents were allowed as the escape therapy.
Outcomes
The primary outcome measure was change in mRSS at 12 months. The same 
assessor performed the mRSS measurement at each time point during the trial. Live 
demonstration and standardization of mRSS for the trial occurred during an investigator 
meeting prior to study initiation, where it was agreed to use the average score at each 
anatomical site[12]. Secondary outcome measures included: (1) change from baseline 
to months 1, 3, 6, and 9 in mRSS; (2) change from baseline to months 1, 3, 6, 9 and 12 
in 28-swollen and tender joint count; (3) change from baseline to months 3, 6 and 12 in 
patient global assessment for overall disease, physician global assessment for overall 
disease, PROMIS-29 v2 Profile, health assessment questionnaire-disability index (HAQ-
DI), Scleroderma-HAQ-DI visual analogue scales (VAS) assessing pain, burden of 
digital ulcers, Raynaud’s, gastrointestinal involvement, breathing, and overall disease, 
and UCLA Gastrointestinal Tract (GIT) 2.0; and (4) change from baseline to months 6 
and 12 in FVC% predicted, and the American College of Rheumatology Combined 
Response Index in Systemic Sclerosis (ACR-CRISS, a composite end point that 
captures cardio-pulmonary-renal involvement and change in mRSS, HAQ-DI, patient 
global assessment, physician global assessment, and FVC% predicted).
The exploratory end points included: (1) change from baseline to months 3, 6 and 12 
in interference with the patient’s physical functioning related to skin involvement and 
pain intensity due to SSc over the previous week on a 0-150 mm VAS; (2) proportion of 
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(3) change from baseline in body mass index and digital ulcer burden at 12 months; and 
(4) change from baseline to months 6 and 12 in DLCO% predicted (corrected for 
hemoglobin) and FVC (in ml).
Safety end points were: (1) proportion of participants experiencing AEs; (2) 
incidence of AEs, serious AEs (SAEs), and AEs of special interest; (3) treatment 
discontinuation due to AEs; and (4) changes in clinical laboratory tests, vital signs, and 
physical examination results over time. The study was overseen by a Data and Safety 
Monitoring Committee that reviewed study conduct and safety outcomes approximately 
every six months.  
RNA-sequencing, Read Alignment and Gene Expression Calculation
Skin biopsy (3 mm) of the involved forearm skin was performed at each site, at 
baseline and at months 3 and 6. Biopsies were stored in RNAlater® and skin biopsies 
were processed for RNA as previously reported[13]. Machine learning was used to 
classify biopsies into intrinsic gene expression subsets. RNA-seq data (RPKM) were 
normalized and baseline skin biopsies were classified into Inflammatory, Normal-like or 
Fibroproliferative intrinsic gene expression subsets[13]. For details on the methodology, 
see Supplementary Text 1.
Statistical Analysis
This study was sized based on practical considerations rather than a desired power 
for a pre-specified difference. We planned to screen 121 patients to randomize 86 
participants. With this sample size, we calculated we could detect an effect size of at 
least 0.66 in the primary end point with 80% power, 5% two-sided Type I error and 15% 
drop-out (two-sample t test, East 5.4). This effect size translates into a treatment 
difference in change from baseline to month 12 in mRSS of 5.3, with an SD of 8 
points[14].  Sample sizes to detect published minimal clinically important differences for 
endpoints used in diffuse systemic sclerosis are detailed in Supplementary Text 2; that 
provide context on the sample size needed for a confirmatory study.
The main analysis set for efficacy was the modified intention to treat (mITT) 
population, defined as all randomized participants who received at least one dose of 
study medication. We analysed the primary end point using a linear mixed model as 
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of treatment failure; therefore, we censored primary end point data after initiation of 
escape therapy. In an additional sensitivity analysis, we applied the same model using 
all mRSS values (i.e., no censoring after escape therapy). Adjusted least squares (LS) 
means, standard errors (SE), 95% confidence intervals (CI), and two-sided p-values for 
between-treatment comparisons are provided.  Safety outcomes are summarized by 
treatment group using descriptive statistics; no tests were performed.
Analyses of all secondary end points used the same approach as for the primary 
end point, except for the ACR-CRISS that used a non-parametric approach; these are 
detailed in the Supplementary Text 2. No adjustments for multiplicity were made, thus 
p-values for secondary and exploratory outcomes should be interpreted with caution.  In 
addition, Supplementary Text 2 also provides the analysis approach for gene signature 
data. The full statistical analysis plan was finalized before unblinding. SAS version 9.4 
was used for all statistical analyses. 
Results
One hundred sixty-nine participants were screened for eligibility and 88 (44 in each 
treatment group) were randomized at 22 centers in the US, Canada and UK between 
September 22, 2014 and March 15, 2017 (Figure 1). Thirty-four (77%) and 35 (80%) 
completed the 12-month trial in the abatacept and placebo groups, respectively. At 12 
months, 7 (16%) and 16 (36%) in the abatacept and placebo groups, respectively, had 
received escape therapy for worsening dcSSc (Supplementary Table 1). Eighty-eight 
participants were included in the mITT and safety analyses and 85 in the per-protocol 
analysis (43 in abatacept and 42 in placebo). Similar numbers of patients withdrew in 
each group. In the abatacept group, ten patients withdrew due to the following reasons: 
investigator withdrew consent (N=3), subject withdrew consent (N=2), lost to follow up 
(N=2), death (N=2), and worsening dcSSc (N=1). In the placebo group, nine patients 
withdrew due to following reasons: investigator withdrew consent (N=1), subject 
withdrew consent (N=4), lost to follow up (N=1), death (N=1), relocation (N=1), and 
worsening dcSSc (N=1). Compliance with the study drug was >98% (one participant in 
the placebo group had compliance <80%). Estimated study medication exposure was 
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(9.1 to 10.8) months in the placebo group. The demographic and baseline disease 
characteristics were balanced between the treatment groups (Table 1).  
The primary outcome measure was not statistically significant – the LS mean 
change (SE) in mRSS was -6.24 (1.14) in the abatacept group and -4.49 (1.14) in the 
placebo group, with a treatment difference of -1.75 (95% CI -4.93, 1.43; Table 2 and 
Figure 2). Sensitivity analyses using the per-protocol population and incorporating all 
values after escape therapy in the mITT population provided comparable results (Table 
2). There also were no statistically significant differences in the change in mRSS at 
months 1, 3, 6, and 9 (Supplementary Table 2). 
There were statistically significant and clinically meaningful treatment differences in 
LS mean improvements at 12 months in HAQ-DI (-0.28, p=0.005, Table 2). There were 
no statistical differences in the swollen and tender joint counts between abatacept and 
placebo at 12 months (LS mean difference 0.75 [0.84], p=0.37 and 0.76 [1.28], 
respectively, p=0.55). In addition, there were statistically significant and clinically 
meaningful improvement in a new composite index, the ACR-CRISS, that favored 
abatacept. The median change in ACR-CRISS score was 0.68 (0.99) vs. 0.01 (0.75), 
p=0.03 at 12 months with proportion of patient who improved by ≥ 0.60, the clinically 
meaningful cutpoint[15]  significantly higher in the abatacept group (62.8% vs. 37.2%, 
p=0.01 using Cochran-Mantel-Haenszel test, adjusting for duration of dcSSc) . Other 
secondary outcomes are presented in Table 2 and Supplementary Table 2.
In analyses of exploratory end points, the proportion of participants who decreased 
in mRSS by ≥5 units (a clinically important improvement)[16] was similar in abatacept 
and placebo (Supplementary Table 3). When the change in mRSS at 12 months was 
evaluated by disease duration (≤18 months vs. >18 to ≤36 months) in an ad hoc 
analysis, numerically greater treatment effects were seen in mRSS in early disease 
(≤18 months; n=53) than in later disease (>18 to ≤36 months; n=35). LS mean changes 
of mRSS in the abatacept group were -5.71 and -6.62 units in the early and later 
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resulted in LS mean (95% CI) treatment difference of -2.73 (-6.57, 1.11) in early disease 
(p=0.16) and -0.44 (-6.10, 1.11) in later disease (p=0.88). 
A total of 23 (26%) participants required escape therapy for their worsening dcSSc, 
with a larger proportion requiring escape in the placebo group [16 (36%)] than in the 
abatacept group [7 (16%)]. The reasons for escape therapy included: worsening skin (8 
in placebo and 4 in abatacept), worsening ILD (2 in placebo), polyarthritis (3 in placebo), 
and overall worsening disease (4 in placebo and 4 in abatacept). There was no increase 
in infections among those who were started on escape therapy and continued on 
abatacept (1 event; 0.4 person-year) vs. those who did not start escape therapy (27 
events; 0.8 person-year). In comparison, participants on placebo who were started on 
escape therapy had 3 events (0.6/person-year) vs. 40 events (1.2/person-year) among 
those who did not start escape therapy. 
Gene expression in skin biopsies was analyzed in 84 patients at baseline 
(abatacept, N=43; placebo, N=41). No systemic biases were found related to collection 
site, time of biopsy, or the RNA-seq analysis. Intrinsic gene expression subset (e.g., 
Inflammatory, Normal-like, Fibroproliferative) was assigned using a machine learning 
classifier before the unblinding of the study. At baseline, 33 (39%) patients were 
classified as Inflammatory, 33 (39%) were classified as Normal-like, and 18 (21%) were 
classified as Fibroproliferative.  Participants with earlier disease (disease duration < 18 
months) were more likely to be part of the inflammatory subset (21/33, 64%) or normal-
like (23/33, 70%) than fibroproliferative (7/18, 39%).  There were no significant 
differences between the distribution of intrinsic gene expression subsets at baseline in 
each treatment arm (Supplementary Table 4). LS mean change in mRSS over 12 
months was significantly different between the abatacept and placebo for the 
Inflammatory (p<0.001) and Normal-like subgroups (p=0.03) (Supplementary Table 5 
and Figure 3), but there was no difference in the Fibroproliferative subset (p=0.47). For 
FVC% predicted, the Fibroproliferative subset showed a numerical increase in FVC% in 
the abatacept arm (p=0.19) while all other groups showed decreases in FVC%. All gene 
expression subgroups showed numerical decreases in HAQ-DI in the abatacept arm 
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Abatacept was found to be generally safe with no new safety signals, with lower 
numbers of participants experiencing AEs, infectious AEs, and SAEs compared to the 
placebo group (Table 3). More participants experienced SAEs in the placebo group 
(27%) vs. abatacept group (20%; Table 3). These included more non-infectious SAEs 
(23% vs. 16%) and the same number of infectious SAEs (5% each). In addition, more 
participants in the placebo group dropped out due to AEs (6 [14%] vs. 5 [11%] in 
abatacept). Renal crisis occurred in three participants (days 11, 25, and 46 after 
initiation of study medication) in the abatacept group vs. one participant in placebo 
group (day 56 after starting study medication). The number of participants with 
treatment emergent AEs by severity grade were similarly distributed among the two 
treatments, with a total of 36 (82%) in abatacept and 40 (91%) in placebo experiencing 
an AE (Supplementary Table 6). There were no cases of tuberculosis during the trial. 
No significant laboratory abnormalities were noted—one participant in each group had a 
hemoglobin decline of >2 gm/dL related to dcSSc (among participants with baseline 
values > 8 gm/dL). There were 20 AEs of special interest in the abatacept group and 26 
in the placebo group, including one injection site reaction in the abatacept group 
(Supplementary Table 7). 
Three deaths occurred in the study. One participant died due to cardiac arrest at 310 
days after starting the study medication (placebo); this death was not considered related 
to the study medication. Two participants experienced scleroderma renal crisis leading 
to death in the abatacept group—one died at day 11 after randomization due to renal 
crisis (considered not related to the study medication) leading to respiratory failure 
(considered related to the study medication). The second participant was admitted due 
to gastrointestinal dysmotility and myositis at day 25 and then had renal crisis at day 46; 
both were considered not related to the study medication. 
Discussion
In this Phase 2 trial, we showed that abatacept is well tolerated in early dcSSc. 
Although we did not achieve a statistically significant treatment difference in the primary 
efficacy end point – the change from baseline in mRSS at 12 months – there were 
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function and ACR-CRISS. In addition, a larger proportion of participants required 
immunomodulatory escape therapy with placebo vs. abatacept, further supporting the 
favorable impact of abatacept. In addition, this is the first prospective trial showing the 
intrinsic gene expression subsets can predict clinical outcome measures with greater 
precision. 
Skin involvement was chosen as the primary outcome measure, as it is an important 
concern for patients due to its relationship to disability caused by small and large joint 
contractures, pruritus, and allodynia[17]. Skin thickness, as assessed by mRSS, is a 
feasible, reliable, valid outcome measure and is sensitive to change[12]. In addition, 
mRSS is utilized by scleroderma physicians to assess for worsening and improvement 
of skin involvement[1]. In early disease, skin involvement is a surrogate for internal 
organ involvement and mortality[18, 19]. Due to this, mRSS has been incorporated as 
the primary end point in early SSc trials[20]. However, statistical negative results in this 
trial is similar to recent published[20] and presented[21] data from studies of anti-IL-6 
receptor in the treatment of SSc. This occurred despite recruitment of a study 
population in this trial with early disease (mean disease duration of 1.59 years); 60% of 
patients were recruited within 18 months of diagnosis, and only 14% had been treated 
with background immunosuppressive therapy. There was a significant heterogeneity in 
mRSS trajectory over the 12-month study period (Supplementary Table 3) [22, 23], 
which is likely driven by the autoantibodies[24] and skin gene expression profile[25]. 
Abatacept therapy did produce a clinically meaningful and statistically significant 
difference over placebo in a validated measure of function, the HAQ-DI[26] and 
numerical improvements in other patient-reported outcome measures (although many 
did not achieve clinically meaningful thresholds). These changes are important, as they 
directly address the FDA mandate to assess how a patient feels, functions, and survives 
(FDA Code of Federal Regulations, Title 21). The efficacy of abatacept is also 
suggested by the lower proportion of participants who required escape therapy for 
worsening in dcSSc relative to placebo (26% vs 36%, respectively). These data should 
be interpreted with caution due to no adjustments for multiplicity. 
In addition, there were statistically significant and clinically meaningful improvement 
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was designed to capture the global or holistic evaluation of the likelihood of 
improvement in early SSc. ACR-CRISS is based on a probability score of 0.0 (no 
improvement) to 1.0 (marked improvement with an improvement of ≥ 0.60 considered 
as clinically meaningful) and includes two steps. The first step assesses for worsening 
or incident cases of cardio-pulmonary-renal involvement and gives a score of 0.0. For 
those who do not meet Step 1, a probability score is calculated that incorporates 
changes in five physical or functional areas — mRSS (assessment of skin), FVC% 
predicted (assessment of lungs), HAQ-DI (measure of patient function), patient global 
assessment, and physician global assessment. The median change in ACR-CRISS 
score was 0.68 (0.99) vs. 0.01 (0.75), p=0.03 with proportion of patient who improved by 
≥ 0.60 significantly higher in the abatacept group. These results are similar to recent 
data from a Phase 3 trial of tociluzimab[21] and highlights the importance of global 
assessment in a multisystem heterogeneous disease.
Participants on placebo had greater numbers of AEs, AEs leading to discontinuation 
and SAEs, highlighting the safety of abatacept in SSc. This was also true in those who 
were on abatacept and other immunomodulatory therapies—data supported by studies 
of other rheumatic diseases where abatacept has been used with immunosuppressive 
therapy[27, 28].
There were three deaths in the trial, two in the abatacept group and one in the 
placebo group. Both deaths in the abatacept group were related to scleroderma renal 
crisis, a dreaded complication in early SSc. There was one additional case of 
scleroderma renal crisis in the abatacept group that did not result in death. All three 
cases occurred early in the disease (11-46 days after randomization), while the one 
case in the placebo group occurred 56 days after randomization. Inhibition of Treg 
function prior to reduction in the numbers and activity of pathogenic effector T cells in 
abatacept-treated patients could account for early flares but eventual reduction in 
disease activity in SSc[29, 30], but data are needed to validate this hypothesis.
A prior pilot study of abatacept in SSc with molecular gene expression data in skin[9] 
found that four of five patients who improved on abatacept, as determined by change in 
mRSS, were in the Inflammatory subset while the other patient who improved was in the 















This article is protected by copyright. All rights reserved
for immune pathways, including the CD28 and CTLA4 receptors—the target of 
abatacept. In this trial, we were able to test and support our a priori hypothesis that the 
Inflammatory subset shows a significant decline in mRSS during abatacept therapy. The 
results are especially interesting and novel considering the likely mechanism of action 
for abatacept as a targeted immunomodulator.  On this basis, it would be expected that 
cases showing the Inflammatory gene signature would be most likely to demonstrate 
treatment effect in the skin (Figure 3).  The most striking difference for mRSS changes 
for both the actual and estimated plots is for the Inflammatory subset.  There is marked 
divergence of the trajectory for MRSS change in the Inflammatory cases compared with 
the other intrinsic subsets, that reaches statistical significance, and no apparent impact 
for the Fibroproliferative subgroup (Supplementary Table 5).  In contrast, for FVC 
change, which may reflect lung fibrosis[31], it is only the Fibroproliferative subset that 
showed trends that favored abatacept.  This points towards different potential molecular 
pathology between the skin and lung in SSc and is consistent with impact of abatacept 
on different components of the disease biology at different sites.  It is also notable that 
mRSS is improved by abatacept whereas for FVC the apparent impact in 
Fibroproliferative cases is to prevent decline.  These data are consistent with results 
from the pilot study of abatacept [9] and extend these findings, for the first time, to a 
large placebo-controlled trial that shows intrinsic skin gene expression subsets may 
predict differential response to a targeted biological therapy.  This has implication for 
stratification of cases according to intrinsic gene expression subsets to maximize the 
number of informative SSc cases in clinical trials, and potentially for future clinical 
practice.
Our study has many strengths.  First, we included experienced sites and were able 
to recruit participants with early active disease. Second, despite a large proportion of 
participants who went on escape therapy (26%), we made every effort to continue 
follow-up of these participants in the trial and capture actual data. Third, we continued to 
build a body of evidence about the potential utility of ACR-CRISS as an alternative 
primary endpoint to the use of changes in skin thickness, given the number of negative 
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by statistical significant results of the proof-of-concept trial of Lenabasum[32] (ACR 
CRISS was the primary outcome measure) and post-hoc and planned analyses in the 
Phase 2 and Phase 3 data with tociluzimab[21, 33] where mRSS has not been able to 
differentiate study medication vs. placebo in these trials.  Last, one of the novel aspects 
of this study was the ascertainment of intrinsic gene expression-based subsets 
(Inflammatory, Fibroproliferative or Normal-like) at baseline that could be integrated into 
a subgroup analysis for potential treatment effect. 
Study limitations include the lack of positive trials in early dcSSc that could provide 
guidance for the sample size calculation; and missing data, which we addressed using 
mixed models and multiple imputation—both valid under the missing at random 
assumption. We did not adjust for multiple comparisons and control the Type I error for 
secondary and exploratory endpoints; thus, we cannot make definitive statements about 
these outcomes and should be considered hypotheses generating.  We considered both 
the clinical importance of abatacept effects, the totality of the study data, and the 
literature on other biologics in SSc in deriving conclusions for our study. We allowed 
background low dose prednisone (as done universally in trials of early SSc) at the study 
entry and 14% were taking low-dose prednisone at baseline visit. The impact of 
background prednisone on skin gene expression data is unknown (personal 
communication: Dr Michael Whitfield) and should be explored in future analyses. We 
have not reported the autoantibodies data and its relationship to outcome measures—
we plan to perform these in a central laboratory in near future. Finally, although the 
participants are representative of other recent trials in early dcSSc, these may differ 
from patients seen in clinics[34].  
In summary, abatacept was well tolerated, but change in mRSS was not statistically 
significant. Secondary outcome measures showed some evidence in favor of abatacept. 
A Phase 3 trial should be conducted before drawing definitive conclusions about the 
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Figures legends:
Figure 1: Enrollment of Participants and Study Flow
Figure 2: Change in the modified Rodnan skin score during 12-month period
Figure 3: Observed average change (left panels) and estimated average change 
from baseline in MRSS, FVC% and HAQ-DI (right panels) in the Placebo and 
Abatacept group and in the three intrinsic gene expression subsets. In each plot, 
vertical bars represent +/- 1 standard error. Estimates are obtained from a linear 
mixed model fitted to the change from baseline in MRSS, FVC% and HAQ-DI, 
respectively, with predictors: MRSS, FVC% and HAQ-DI at baseline, respectively, 
month in the study, treatment group, interaction of treatment group and month 
and a subject-specific random effect.







Age, Years, mean 
(SD)
49 (13) 49 (13) 50 (12)
Female, N (%) 66 (75%) 35 (80%) 31 (70%)
White, N (%) 72 (82%) 37 (84%) 35 (80%)
Not Hispanic or 
Latino, N (%)
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Disease Duration, 
Years*, mean (SD) 
1.59 (0.81) 1.52 (0.79) 1.66 (0.84)
Disease <18 Months, 
N (%)
53 (60%) 27 (61%) 26 (59%)
mRSS, mean (SD) 22.45 (7.65) 21.57 (7.33) 23.34 (7.95)
FVC% Predicted, 
mean (SD)
85.4 (15.10) 86.5 (16.60) 84.2 (13.50)
DLCO% Predicted, 
Corrected for Hgb, 
mean (SD)





4.09 (2.38) 4.31 (2.56) 3.88 (2.21)
HAQ-DI, mean (SD) 
[theoretical range 0-3]





4.77 (1.67) 4.76 (1.67) 4.77 (1.67)
Tendon Friction 
Rubs, N (%)
32 (36%) 13 (30%) 19 (43%)
Large Joint 
Contractures, N (%)
63 (72%) 32 (73%) 31 (70%)




3.75 (5.70) 3.86 (5.85) 3.64 (5.62)
Proportion of 
Participants with > 1 
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Swollen Joint Count, 
N (%)
Use of Prednisone,   
N (%)
12 (14%) 5 (11%) 7 (16%)
Prednisone dose in 
mg, mean (SD)
7.9 (2.6) 7.0 (2.7) 8.6 (2.4)
*Disease onset was defined as first non-Raynaud’s sign or symptoms; mRSS=modified 
Rodnan skin score; FVC=Forced vital capacity, DLCO =Diffusion capacity of carbon 
monoxide










(Change from Baseline to 
Month 12)
LS mean (SE)




Primary analysis: mITT with 
values censored after escape 
therapy
-4.49 (1.14) -6.24 (1.14) -1.75 (-4.93, 1.43) 0.28
Sensitivity analysis 1: per 
protocol with values censored 
after escape therapy
-4.63 (1.15) -6.25 (1.13) -1.62 (-4.79, 1.55) 0.31
Sensitivity analysis 2: mITT with 
values not censored after 
escape therapy
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Patient Global Assessment     
(0-10)*
-0.09 (0.46) -0.31 (0.42) -0.22 (-1.45, 1.01) 0.73
Physician Global Assessment 
(0-10)*
-0.35 (0.32) -1.30 (0.29) -0.95 (-1.80, -0.10) 0.03








HAQ-DI (0-3)* 0.11 (0.07) -0.17 (0.07) -0.28 (-0.47, -0.09) 0.005
S-HAQ-Overall VAS (0-150)* 3.52 (6.05) -7.42 (5.64) -10.94 (-27.27, 5.38) 0.19
S-HAQ-Breathing VAS (0-150)* 16.95 (5.85) 9.30 (5.51) -7.65 (-23.60, 8.30) 0.34
S-HAQ-Raynaud’s VAS (0-150)* -3.64 (7.17) 7.58 (6.60) 11.22 (-8.04, 30.47) 0.25
S-HAQ-Digital Ulcers VAS       
(0-150)*
8.67 (5.52) -3.18 (5.13) -11.85 (-26.70, 3.01) 0.12
S-HAQ-GI VAS (0-150)* 8.01 (6.42) 9.98 (6.00) 1.96 (-15.40, 19.33) 0.82
Swollen Joint Count (0-28)* -0.86 (0.60) -0.11 (0.60) 0.75 (-0.91, 2.41) 0.37
Tender Joint Count (0-28)* -1.47 (0.91) -0.71 (0.90) 0.76 (-1.75, 3.27) 0.55
PROMIS-29 Physical Function -0.17 (0.69) -1.54 (0.65) -1.36 (-3.23, 0.50) 0.15
PROMIS-29 Anxiety* -1.09 (1.37) -3.50 (1.31) -2.41 (-6.15, 1.32) 0.20
PROMIS-29 Depression* -0.41 (1.20) -0.02 (1.13) 0.39 (-2.86, 3.64) 0.81
PROMIS-29 Fatigue* -0.98 (1.36) -0.65 (1.29) 0.33 (-3.37, 4.03) 0.86
PROMIS-29 Sleep Disturbance* -0.21 (0.62) -0.31 (0.57) -0.10 (-1.76, 1.57) 0.91
PROMIS-29 Pain Interference* -1.56 (1.22) -4.10 (1.13) -2.53 (-5.81, 0.74) 0.13
PROMIS-29 Social Roles* -1.26 (1.14) -1.11 (1.07) 0.15 (-2.93, 3.24) 0.92
PROMIS-29 Pain Intensity       
(0-10)*
-0.18 (0.33) -0.72 (0.32) -0.54 (-1.44, 0.37) 0.24


























ACR CRISS at 12 Months 0.02 (0.75) 0.72 (0.99) 0.03**
LS = least squares; SE = standard error; CI = confidence interval
For primary and sensitivity analyses, the estimates and p-values are from a linear mixed model with 
treatment group, month (3, 6, 9 and 12), treatment group x month interaction, and baseline mRSS 
as fixed effects and participant as a random effect.
For secondary analyses, the estimates and p-values are from a linear mixed model with treatment 
group, month, treatment group x month interaction, duration of dcSSc (≤18 vs >18 to ≤36 months), 
and baseline variable as fixed effects and participant as a random effect. 
mITT population includes all of the randomized participants who received at least one dose of study 
medication. Per protocol population includes mITT participants who did not experience a major 
protocol deviation, defined as eligibility criteria violations for which no exemption was granted, 
study drug compliance <80% and >120% , and receipt of escape medication prior to month 3.  
✢P values should be interpreted with caution as they are not adjusted for multiplicity. 
*Higher score denotes worse symptom
**van Elteren test, adjusting for duration of dcSSc. Five participants in each group had cardio-
pulmonary-renal involvement and were given a probability score of 0.0. Multiple imputation was 
used to address missing follow-up data in mRSS, FVC% predicted, HAQ-DI and patient and 
physician global assessments, allowing calculation of the ACR-CRISS score. 





Participants with > 1 AE 40 (91%) 35 (80%)
Participants with > 1 infectious AE 25 (57%) 19 (43%)
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Participants with > 1 SAE 12 (27%) 9 (20%)







Atrial flutter with conduction defects 1 [b]
Cardiac arrest 1
Congestive heart failure 1 [b]
Myocardial infarction/acute coronary 
syndrome
1 [c] 1
Pulmonary arterial hypertension 1 [b] 1 [d]




Dysphagia 1 1 [e]
Erosive esophagitis 1
Gastric Antral Vascular Ectasia 1






Basal cell skin carcinoma 1
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Respiratory Disorders
Respiratory failure 1 [g]
Renal Disorders
Scleroderma renal crisis 1 3 [e] [g]
Vascular Disorders
Digital ischemia 1 [a]
Mental Disorders
Depression with suicidal ideation 1 [c]
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Assessed for eligibility (n=169)
Allocated to Abatacept (n=44)
• Received allocated intervention (n=44)
Excluded (n=81)
• Did not meet inclusion criteria (n=42)
• Declined to participate (n=31)
• Other reasons (n=8)
44 included in the analysis
Allocated to Placebo (n=44)
• Received allocated intervention (n=44)
1 lost to follow up
8 Withdrew
• 4 subjects withdrew consent, 1 investigator 
withdrew consent, 1 death,  1 relocation, 1 
worsening disease
• 2 discontinued intervention
• Worsening dcSSc 
44 included in the analysis
2 lost to follow up
8 Withdrew
• 2 subjects withdrew consent, 3 investigator 
withdrew consent, 2 deaths, 1 worsening 
disease
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